Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas

APMIS

Volumn 119, Issue 4-5, 2011, Pages 296-303

  Olesen, Uffe Høgh ^a   Hastrup, Nina ^a   Sehested, Maxwell ^a  

^a Rigshospitalet   (Denmark)

Author keywords

APO866; Biomarkers; Chemoprotection; Malignant lymphoma; Nicotinamide phosphoribosyltransferase; Nicotinic acid phosphoribosyltransferase

Indexed keywords

BIOLOGICAL MARKER; DAPORINAD; ENZYME INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; TP 201565; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MOUSE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOSYLTRANSFERASES; REED-STERNBERG CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79954878322     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02733.x     Document Type: Article

References (24)

1. Pollak N, Dolle C, Ziegler M. The power to reduce: pyridine nucleotides-small molecules with a multitude of functions. Biochem J 2007;402:205-18.
2. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008;88:841-86.
3. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20:130-8.
4. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009;15:20-8.
5. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008;181:4685-95.
6. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007;130:1095-107.
7. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
8. Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Hoglund M, Tholander B, et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 2001;12:821-7.
9. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009;113:3276-86.
10. Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804.
11. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in NAPRT1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
12. Olesen UH, Thougaard AV, Jensen PB, Sehested M. A preclinical study on the rescue of normal tissue by nicotinic acid in high dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 2010;9:1609-17.
13. Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai SI, et al. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer 2010;10:677.
14. Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009;54:688-98.
15. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002;32:3225-34.
16. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7.
17. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, et al. Signatures of the immune response. Immunity 2001;15:375-85.
18. Teague TK, Hildeman D, Kedl RM, Mitchell T, Rees W, Schaefer BC, et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci U S A 1999;96:12691-6.
19. Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol 2001;2:316-24.
20. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002;99:1503-8.
21. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001;294:870-5.
22. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27.
23. Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7.
24. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.